The city of Santa Monica, California, currently has 76 active clinical trials seeking participants for Cancer research studies.
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: UCLA Hematology/Oncology-Santa Monica, Santa Monica, California
Conditions: Breast Cancer
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Recruiting
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors. The study will be conducted in 3 parts: Part A: MPT-0118 dose-escalation Part B: MPT-0118 dose-escalation in combination with pembrolizumab Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2021
Locations: St. John's Cancer Center, Santa Monica, California
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
Evaluation of the PhageTech Virus BioResistor
Recruiting
To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/12/2021
Locations: Providence Saint John's Health Center and the Saint John's Cancer Institute, Santa Monica, California
Conditions: Bladder Cancer